procarbazine has been researched along with Central Nervous System Neoplasm in 57 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter phase II study was conducted to assess the efficacy of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consolidation reduced-dose whole-brain radiotherapy (rdWBRT) and cytarabine in primary CNS lymphoma." | 9.17 | Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. ( Abrey, LE; Correa, DD; Curry, R; DeAngelis, LM; Grant, B; Grimm, S; Karimi, S; Lai, RK; Morris, PG; Omuro, A; Panageas, K; Raizer, JJ; Reiner, AS; Schiff, D; Shah, G; Yahalom, J, 2013) |
| "After surgery, patients aged < or = 70 years, with World Health Organization grade 3 or 4 astrocytoma, were randomized to radiotherapy alone (RT) or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy (RT-PCV) given at 6-week intervals to a maximum of 12 courses (procarbazine 100 mg/m2 days 1 to 10, lomustine 100 mg/m2 day 1, and vincristine 1." | 9.09 | Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. ( , 2001) |
| "The optimal high-dose methotrexate (HDMTX)-based combination therapy for primary central nervous system lymphoma is unknown." | 8.12 | Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma. ( Avni, B; Gatt, ME; Goldschmidt, N; Grisaro, S; Gural, A; Lavie, D; Lebel, E; Linetski, E; Lossos, A; Makranz, C; Nachmias, B; Rosenberg, S; Saban, R; Shaulov, A; Siegal, T; Vainstein, V; Zimran, E, 2022) |
| "We studied the clinical effects of high-dose methotrexate(HD-MTX)combined with rituximab and vincristine in 5 elderly patients, aged 65-83 years, with diffuse large B-cell lymphoma of the central nervous system(DLBCL CNS)." | 7.85 | [Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System]. ( Goto, T; Nagura, E; Nakashima, M; Okamoto, S; Tanaka, M, 2017) |
| "This retrospective single-center study assessed the feasibility, outcomes, and side-effects of high-dose methotrexate (HD-MTX) plus procarbazine in the treatment of immunocompetent patients with primary central nervous system lymphoma (PCNSL)." | 7.81 | Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience. ( Hide, T; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Yano, S, 2015) |
| "The authors investigated objective response rate to high dose methotrexate (HDMTX)-based combination chemotherapy in primary central nervous system lymphoma (PCNSL), and sought to identify factors that influence response to HDMTX-based combination therapy." | 7.77 | Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma. ( Kim, YZ; Lee, EH; Sung, KH, 2011) |
| "To assess the efficacy, acute toxicity, and delayed neurotoxicity of intermediate-dose methotrexate (MTX)-containing chemotherapy without whole-brain radiotherapy in the treatment of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a retrospective analysis of elderly patients (N = 17; median age 67) with newly diagnosed PCNSL who were treated with chemotherapy alone at Tsukuba University Hospital from January 2005 to December 2009." | 7.76 | A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma. ( Chiba, S; Hasegawa, Y; Matsumura, A; Okoshi, Y; Sakamoto, N; Takano, S; Taoka, K, 2010) |
| "To assess the feasibility and the activity, as well as the efficacy to treat meninges, of chemotherapy (CHT) containing high-dose methotrexate (HD-MTX) followed by radiation therapy (RT), without intrathecal CHT, in patients with primary central nervous system lymphoma." | 7.71 | Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. ( Bernardi, M; Camba, L; Ciceri, F; Dell'Oro, S; Ferreri, AJ; Ponzoni, M; Reni, M; Spina, M; Terreni, MR; Tomirotti, M; Villa, E, 2001) |
| "Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity." | 6.82 | Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016) |
| "A multicenter phase II study was conducted to assess the efficacy of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consolidation reduced-dose whole-brain radiotherapy (rdWBRT) and cytarabine in primary CNS lymphoma." | 5.17 | Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. ( Abrey, LE; Correa, DD; Curry, R; DeAngelis, LM; Grant, B; Grimm, S; Karimi, S; Lai, RK; Morris, PG; Omuro, A; Panageas, K; Raizer, JJ; Reiner, AS; Schiff, D; Shah, G; Yahalom, J, 2013) |
| "After surgery, patients aged < or = 70 years, with World Health Organization grade 3 or 4 astrocytoma, were randomized to radiotherapy alone (RT) or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy (RT-PCV) given at 6-week intervals to a maximum of 12 courses (procarbazine 100 mg/m2 days 1 to 10, lomustine 100 mg/m2 day 1, and vincristine 1." | 5.09 | Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. ( , 2001) |
| " Approximately two thirds of patients with the more aggressive form (anaplastic oligodendroglioma) have shown substantial response to first-line procarbazine/lomustine/vincristine (PCV) therapy." | 4.81 | Chemotherapy for the treatment of oligodendroglial tumors. ( Chinot, O, 2001) |
| "The optimal high-dose methotrexate (HDMTX)-based combination therapy for primary central nervous system lymphoma is unknown." | 4.12 | Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma. ( Avni, B; Gatt, ME; Goldschmidt, N; Grisaro, S; Gural, A; Lavie, D; Lebel, E; Linetski, E; Lossos, A; Makranz, C; Nachmias, B; Rosenberg, S; Saban, R; Shaulov, A; Siegal, T; Vainstein, V; Zimran, E, 2022) |
| "We studied the clinical effects of high-dose methotrexate(HD-MTX)combined with rituximab and vincristine in 5 elderly patients, aged 65-83 years, with diffuse large B-cell lymphoma of the central nervous system(DLBCL CNS)." | 3.85 | [Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System]. ( Goto, T; Nagura, E; Nakashima, M; Okamoto, S; Tanaka, M, 2017) |
| "This retrospective single-center study assessed the feasibility, outcomes, and side-effects of high-dose methotrexate (HD-MTX) plus procarbazine in the treatment of immunocompetent patients with primary central nervous system lymphoma (PCNSL)." | 3.81 | Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience. ( Hide, T; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Yano, S, 2015) |
| "The authors investigated objective response rate to high dose methotrexate (HDMTX)-based combination chemotherapy in primary central nervous system lymphoma (PCNSL), and sought to identify factors that influence response to HDMTX-based combination therapy." | 3.77 | Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma. ( Kim, YZ; Lee, EH; Sung, KH, 2011) |
| "To assess the efficacy, acute toxicity, and delayed neurotoxicity of intermediate-dose methotrexate (MTX)-containing chemotherapy without whole-brain radiotherapy in the treatment of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a retrospective analysis of elderly patients (N = 17; median age 67) with newly diagnosed PCNSL who were treated with chemotherapy alone at Tsukuba University Hospital from January 2005 to December 2009." | 3.76 | A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma. ( Chiba, S; Hasegawa, Y; Matsumura, A; Okoshi, Y; Sakamoto, N; Takano, S; Taoka, K, 2010) |
| "Our goals were to evaluate the safety of adding rituximab to methotrexate (MTX)-based chemotherapy for primary CNS lymphoma, determine whether additional cycles of induction chemotherapy improve the complete response (CR) rate, and examine effectiveness and toxicity of reduced-dose whole-brain radiotherapy (WBRT) after CR." | 3.74 | Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. ( Abrey, LE; Correa, DD; DeAngelis, LM; Grant, B; Lai, RK; LaRocca, R; Raizer, JJ; Schiff, D; Shah, GD; Yahalom, J, 2007) |
| "To assess the feasibility and the activity, as well as the efficacy to treat meninges, of chemotherapy (CHT) containing high-dose methotrexate (HD-MTX) followed by radiation therapy (RT), without intrathecal CHT, in patients with primary central nervous system lymphoma." | 3.71 | Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. ( Bernardi, M; Camba, L; Ciceri, F; Dell'Oro, S; Ferreri, AJ; Ponzoni, M; Reni, M; Spina, M; Terreni, MR; Tomirotti, M; Villa, E, 2001) |
| "Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity." | 2.82 | Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016) |
| "To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU." | 2.74 | High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. ( Deckert, M; Feuerhake, F; Finke, J; Ihorst, G; Illerhaus, G; Marks, R; Müller, F; Ostertag, C, 2009) |
| " Parameters were evaluated by age at diagnosis, gender, ethnic origin, pre- and postsurgery Karnofsky Performance Status (KPS) score, limit and amount of surgical resection, histopathologic type, number of chemotherapy courses, time between surgery and radiotherapy, response to combined therapy, and dosage and type of radiotherapy." | 2.70 | Long-term follow-up in managing anaplastic astrocytoma by multimodality approach with surgery followed by postoperative radiotherapy and PCV-chemotherapy: phase II trial. ( Gal, O; Kovner, F; Ron, IG; Vishne, TH, 2002) |
| "He was diagnosed with stage II Hodgkin's lymphoma at the age of 15, and we considered the possibility of newly emerged CNS lymphoma occurring in the immunosuppressive condition after the treatment of Hodgkin's lymphoma." | 2.52 | Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) after treatment for Hodgkin's lymphoma. ( Hirose, S; Mashima, K; Mori, T; Okamoto, S; Shimizu, T; Suzuki, N; Suzuki, S; Yamada, S, 2015) |
| "Temozolomide (TMZ) has established antineoplastic activity in the central nervous system in other disease states, with a favorable toxicity profile." | 1.51 | Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma. ( Brenner, A; Butler, MJ; Faivre, G; Le, I, 2019) |
| " Pretreatment of mice with O6-benzylguanine increased temozolomide-induced mortality, requiring reduction of the dosage from 1200 to 750 mg/m2 on the single-day regimen." | 1.29 | Activity of temozolomide in the treatment of central nervous system tumor xenografts. ( Bigner, DD; Catino, JJ; Dolan, ME; Friedman, HS; Keir, S; Marcelli, S; Pegg, AE; Schold, SC, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (19.30) | 18.2507 |
| 2000's | 21 (36.84) | 29.6817 |
| 2010's | 21 (36.84) | 24.3611 |
| 2020's | 4 (7.02) | 2.80 |
| Authors | Studies |
|---|---|
| Lebel, E | 1 |
| Goldschmidt, N | 1 |
| Siegal, T | 1 |
| Lossos, A | 1 |
| Rosenberg, S | 1 |
| Makranz, C | 1 |
| Linetski, E | 1 |
| Gatt, ME | 1 |
| Gural, A | 1 |
| Saban, R | 1 |
| Lavie, D | 1 |
| Vainstein, V | 1 |
| Zimran, E | 1 |
| Avni, B | 1 |
| Grisaro, S | 1 |
| Shaulov, A | 1 |
| Nachmias, B | 1 |
| Nagane, M | 1 |
| Kaulen, LD | 1 |
| Baehring, JM | 1 |
| Wirdah, A | 1 |
| Djamaludin, N | 1 |
| Syahrir, M | 1 |
| Andayani, YD | 1 |
| Andriani, M | 1 |
| Diansari, Y | 1 |
| Hattori, K | 1 |
| Sakata-Yanagimoto, M | 1 |
| Okoshi, Y | 2 |
| Kato, T | 1 |
| Kurita, N | 1 |
| Yokoyama, Y | 1 |
| Obara, N | 1 |
| Takano, S | 2 |
| Ishikawa, E | 1 |
| Yamamoto, T | 1 |
| Matsumura, A | 2 |
| Hasegawa, Y | 2 |
| Chiba, S | 2 |
| Okamoto, S | 2 |
| Tanaka, M | 1 |
| Goto, T | 1 |
| Nakashima, M | 1 |
| Nagura, E | 1 |
| Faivre, G | 2 |
| Butler, MJ | 1 |
| Le, I | 1 |
| Brenner, A | 1 |
| Morris, PG | 2 |
| Correa, DD | 3 |
| Yahalom, J | 4 |
| Raizer, JJ | 2 |
| Schiff, D | 2 |
| Grant, B | 2 |
| Grimm, S | 1 |
| Lai, RK | 2 |
| Reiner, AS | 2 |
| Panageas, K | 1 |
| Karimi, S | 1 |
| Curry, R | 1 |
| Shah, G | 1 |
| Abrey, LE | 6 |
| DeAngelis, LM | 8 |
| Omuro, A | 7 |
| Makino, K | 1 |
| Nakamura, H | 1 |
| Hide, T | 1 |
| Kuroda, J | 1 |
| Yano, S | 1 |
| Kuratsu, J | 1 |
| Moskowitz, CH | 1 |
| Matasar, MJ | 1 |
| Kaley, TJ | 1 |
| Gavrilovic, IT | 1 |
| Nolan, C | 1 |
| Pentsova, E | 1 |
| Grommes, CC | 1 |
| Panageas, KS | 2 |
| Baser, RE | 1 |
| Sauter, CS | 1 |
| Mashima, K | 1 |
| Suzuki, S | 1 |
| Mori, T | 1 |
| Shimizu, T | 1 |
| Yamada, S | 1 |
| Hirose, S | 1 |
| Suzuki, N | 1 |
| Chinot, O | 3 |
| Taillandier, L | 2 |
| Ghesquieres, H | 1 |
| Soussain, C | 3 |
| Delwail, V | 1 |
| Lamy, T | 1 |
| Gressin, R | 1 |
| Choquet, S | 3 |
| Soubeyran, P | 2 |
| Huchet, A | 1 |
| Benouaich-Amiel, A | 1 |
| Lebouvier-Sadot, S | 1 |
| Gyan, E | 1 |
| Touitou, V | 2 |
| Barrié, M | 1 |
| del Rio, MS | 1 |
| Gonzalez-Aguilar, A | 2 |
| Houillier, C | 3 |
| Delgadillo, D | 1 |
| Lacomblez, L | 1 |
| Tanguy, ML | 1 |
| Hoang-Xuan, K | 4 |
| Khasraw, M | 1 |
| Lee, A | 1 |
| McCowatt, S | 1 |
| Kerestes, Z | 1 |
| Buyse, ME | 1 |
| Back, M | 1 |
| Kichenadasse, G | 1 |
| Ackland, S | 1 |
| Wheeler, H | 1 |
| Nguyen, DT | 1 |
| Cassoux, N | 1 |
| Le Cossec, C | 1 |
| Legarf-Tavernier, M | 1 |
| Costopoulos, M | 1 |
| LeHoang, P | 1 |
| Bodaghi, B | 1 |
| Illerhaus, G | 2 |
| Marks, R | 1 |
| Müller, F | 1 |
| Ihorst, G | 2 |
| Feuerhake, F | 1 |
| Deckert, M | 1 |
| Ostertag, C | 1 |
| Finke, J | 2 |
| Ferreri, AJ | 2 |
| Verona, C | 1 |
| Politi, LS | 1 |
| Chiara, A | 1 |
| Perna, L | 1 |
| Villa, E | 2 |
| Reni, M | 2 |
| Taoka, K | 1 |
| Sakamoto, N | 1 |
| Fritsch, K | 1 |
| Kasenda, B | 1 |
| Hader, C | 1 |
| Nikkhah, G | 1 |
| Prinz, M | 1 |
| Haug, V | 1 |
| Haug, S | 1 |
| Sung, KH | 1 |
| Lee, EH | 1 |
| Kim, YZ | 1 |
| Miwa, A | 1 |
| Sekiguchi, N | 1 |
| Tanimura, A | 1 |
| Homma, C | 1 |
| Shikai, T | 1 |
| Takezako, Y | 1 |
| Yamagata, N | 1 |
| Takezako, N | 1 |
| Gerard, LM | 1 |
| Imrie, KR | 1 |
| Mangel, J | 1 |
| Buckstein, R | 1 |
| Doherty, M | 1 |
| Mackenzie, R | 1 |
| Cheung, MC | 1 |
| Wu, N | 1 |
| Seko, BS | 1 |
| Sierra Del Rio, M | 1 |
| Ricard, D | 1 |
| Navarro, S | 1 |
| Idbaih, A | 1 |
| Kaloshi, G | 1 |
| Elhallani, S | 1 |
| Ater, JL | 1 |
| Zhou, T | 1 |
| Holmes, E | 1 |
| Mazewski, CM | 1 |
| Booth, TN | 1 |
| Freyer, DR | 1 |
| Lazarus, KH | 1 |
| Packer, RJ | 1 |
| Prados, M | 1 |
| Sposto, R | 1 |
| Vezina, G | 1 |
| Wisoff, JH | 1 |
| Pollack, IF | 1 |
| Sato, K | 1 |
| Uchiyama, M | 1 |
| Welch, MR | 1 |
| Brandes, AA | 1 |
| Vastola, F | 1 |
| Basso, U | 1 |
| Berti, F | 1 |
| Pinna, G | 1 |
| Rotilio, A | 1 |
| Gardiman, M | 1 |
| Scienza, R | 1 |
| Monfardini, S | 1 |
| Ermani, M | 1 |
| Bogdhan, U | 1 |
| Hildebrand, J | 1 |
| Frenay, M | 1 |
| De Beule, N | 1 |
| Delattre, JY | 2 |
| Baron, B | 1 |
| Korfel, A | 2 |
| Martus, P | 1 |
| Nowrousian, MR | 1 |
| Hossfeld, DK | 1 |
| Kirchen, H | 1 |
| Brücher, J | 1 |
| Stelljes, M | 1 |
| Birkmann, J | 1 |
| Peschel, C | 1 |
| Pasold, R | 1 |
| Fischer, L | 1 |
| Jahnke, K | 1 |
| Thiel, E | 2 |
| Omuro, AM | 1 |
| Yamanaka, R | 4 |
| Morii, K | 3 |
| Shinbo, Y | 4 |
| Takeuchi, S | 1 |
| Tamura, T | 3 |
| Hondoh, H | 3 |
| Takahashi, H | 4 |
| Onda, K | 3 |
| Tanaka, R | 4 |
| Herrlinger, U | 2 |
| Hebart, H | 1 |
| Kanz, L | 1 |
| Dichgans, J | 2 |
| Weller, M | 2 |
| Partap, S | 1 |
| Spence, AM | 1 |
| Homma, J | 3 |
| Sano, M | 3 |
| Tsuchiya, N | 3 |
| Yajima, N | 3 |
| Hasegawa, A | 1 |
| Carmichael, MG | 1 |
| Shah, GD | 1 |
| LaRocca, R | 1 |
| Gill, P | 1 |
| Litzow, M | 1 |
| Buckner, J | 1 |
| Arndt, C | 1 |
| Moynihan, T | 1 |
| Christianson, T | 1 |
| Ansell, S | 1 |
| Galanis, E | 1 |
| Kakuma, T | 1 |
| Friedman, HS | 1 |
| Dolan, ME | 1 |
| Pegg, AE | 1 |
| Marcelli, S | 1 |
| Keir, S | 1 |
| Catino, JJ | 1 |
| Bigner, DD | 1 |
| Schold, SC | 1 |
| Freilich, RJ | 1 |
| Monjour, A | 1 |
| Dent, S | 1 |
| Eapen, L | 1 |
| Girard, A | 1 |
| Hugenholtz, H | 1 |
| DaSilva, V | 1 |
| Stewart, DJ | 1 |
| Maeda, Y | 1 |
| Matsumoto, K | 1 |
| Kuriyama, M | 1 |
| Ono, Y | 1 |
| Kunishio, K | 1 |
| Tamiya, T | 1 |
| Furuta, T | 1 |
| Ohmoto, T | 1 |
| Chamberlain, MC | 2 |
| Kormanik, PA | 1 |
| Keyaki, A | 1 |
| Nabeshima, S | 1 |
| Waga, S | 1 |
| Wu, HG | 1 |
| Kim, IH | 1 |
| Ha, SW | 1 |
| Park, CI | 1 |
| Bang, YJ | 1 |
| Huh, DS | 1 |
| Brugger, W | 1 |
| Bamberg, M | 1 |
| Küker, W | 1 |
| Dell'Oro, S | 1 |
| Ciceri, F | 1 |
| Bernardi, M | 1 |
| Camba, L | 1 |
| Ponzoni, M | 1 |
| Terreni, MR | 1 |
| Tomirotti, M | 1 |
| Spina, M | 1 |
| Ron, IG | 1 |
| Gal, O | 1 |
| Vishne, TH | 1 |
| Kovner, F | 1 |
| Kochi, M | 1 |
| Ushio, Y | 1 |
| Boiardi, A | 1 |
| Silvani, A | 1 |
| Milanesi, I | 1 |
| Broggi, G | 1 |
| Fariselli, L | 1 |
| Levin, VA | 1 |
| Bashir, RM | 1 |
| Bierman, PJ | 1 |
| Vose, JM | 1 |
| Weisenburger, DD | 1 |
| Armitage, JO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma[NCT00594815] | 52 participants (Actual) | Interventional | 2002-08-28 | Completed | |||
| A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655] | Phase 2 | 51 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)[NCT00596154] | Phase 2 | 33 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Multicenter Randomized Phase II Study of Methotrexate (MTX) and Temozolomide Versus MTX, Procarbazine, Vincristine and Cytarabine for Primary CNS Lymphoma (PCNSL) in the Elderly[NCT00503594] | Phase 2 | 92 participants (Anticipated) | Interventional | 2007-07-31 | Recruiting | ||
| Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy[NCT00989352] | Phase 2 | 56 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old[NCT00002944] | Phase 3 | 428 participants (Actual) | Interventional | 1997-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall Progression Free Survival at 2 years (NCT00594815)
Timeframe: 2 Years
| Intervention | percentage of participants (Number) |
|---|---|
| Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 57 |
The toxicity of this combined regimen will be measured using the NCI CTC version 2.0. (NCT00594815)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma | 52 |
4 reviews available for procarbazine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms | 2022 |
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) after treatment for Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Central Nervous System Neoplasms; Chr | 2015 |
Chemotherapy for the treatment of oligodendroglial tumors.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous S | 2001 |
[Chemo-radiotherapy for malignant brain tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Central Nervous System | 2002 |
27 trials available for procarbazine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.
Topics: Aftercare; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemora | 2017 |
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2015 |
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine | 2016 |
Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2016 |
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Comb | 2009 |
Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2011 |
Ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide therapy for central nervous system recurrence of diffuse large B-cell lymphoma in patients with poor performance status: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2011 |
High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mod | 2011 |
Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Central Nervous System | 2012 |
A prospective study on glioblastoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mod | 2003 |
Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Belgium; Biops | 2003 |
Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2005 |
Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms | 2005 |
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combi | 2007 |
Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cent | 1996 |
PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo | 1996 |
[Combined modality therapy for malignant lymphoma of the primary central nervous system: a preliminary report of a new chemotherapeutic regimen with "PEACE"].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms | 1999 |
Survival improvement with combined radio-chemotherapy in the primary central nervous system lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous | 1999 |
PCV salvage chemotherapy for recurrent primary CNS lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Huma | 2000 |
Treatment for primary CNS lymphoma: the next step.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2000 |
Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Central Nervous System Neo | 2001 |
Long-term follow-up in managing anaplastic astrocytoma by multimodality approach with surgery followed by postoperative radiotherapy and PCV-chemotherapy: phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Central | 2002 |
Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Glioblastoma; Huma | 1992 |
26 other studies available for procarbazine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl | 2022 |
[Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Central N | 2022 |
Primary Central Nervous System Lymphoma in an Immunocompetent Young Adult Patient: A Rare Case.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Huma | 2023 |
[Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2017 |
Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Disea | 2019 |
Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2015 |
Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System | 2011 |
A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neopla | 2010 |
Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neo | 2011 |
Prophylactic intrathecal chemotherapy in primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2012 |
Isolated central nervous system relapse in a patient with diffuse large B cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2012 |
Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2012 |
Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Centra | 2005 |
Relapse of primary CNS lymphoma after more than 10 years in complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mo | 2005 |
Spontaneously relapsing and remitting primary CNS lymphoma in an immunocompetent 45-year-old man.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Central Nervous System Neop | 2006 |
Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy.
Topics: Adult; Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Dexametha | 2007 |
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2007 |
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2008 |
Results of treatment of 112 cases of primary CNS lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2008 |
Activity of temozolomide in the treatment of central nervous system tumor xenografts.
Topics: Animals; Carmustine; Central Nervous System Neoplasms; Dacarbazine; Female; Guanine; Humans; Male; M | 1995 |
[Clinical study of primary central nervous system lymphoma: the role of chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 1997 |
Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Carmustine; Centra | 1998 |
AIDS-related central nervous system lymphomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neopl | 1999 |
Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2001 |
Primary central nervous system lymphoma: a role for adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 1992 |
Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1991 |